Larimar Therapeutics
extends survival in deficient mice | Larimar Therapeutics
Company
Deck Type
Sector
Industry
Deck date
November 2023
Slide
40 of 44
Similar slides by Larimar Therapeutics
See diffirences between slides (animation)
Investor Presentation
October 2022
extends survival in deficient mice | Larimar Therapeutics
Related slides by other companies
Dynatrace
Investor Presentation
February 2022
an efficient land and expand model | Dynatrace
Genprex
Investor Presentation
November 2024
reversed drug induced diabetes in toxin induced mouse model | Genprex
Alkermes
Investor Day
March 2021
enhanced the anti tumor efficacy of in mouse tumors tumor growth inhibition overall survival combination with growth factor pathway inhibitors days vehicle complete responses days in combination with either or not shown resulted in enhanced tumor suppression and survival relative to groups similar results observed with a mouse surrogate of which is a selective inhibitor of the angiogenesis factor alkermes internal data on file the mouse of was used in mouse tumor model | Alkermes
Equillium
Investor Presentation
February 2024
reverses immune mediated hair loss in a mouse model | Equillium
Other recent decks by Larimar Therapeutics
See all presentations (3 decks)
Results
November 2022
Investor Presentation
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights